According to a letter obtained by CNBC, U.S. Senators Angela Alsobrooks and Ron Wyden sent a letter to the Department of Health and Human Services (HHS) on Wednesday, inquiring about the measures the department has taken to mitigate the risks associated with prediction markets related to clinical trials and drug approvals. They also requested materials regarding staff participation in such markets and communications with platforms. The two lawmakers raised concerns over trial participants, research incentives, and potential insider trading risks. CNBC also disclosed that it has a commercial relationship with Kalshi, including a minority equity investment.